SCHEMBL16626743

SCHEMBL16626743

CNCc1cn(S(=O)(=O)c2cccc(Cl)c2Cl)c2cc(Nc3ccc(C)cc3F)ccc12

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 1/20 0.37
PTGS2 P35354 4/20 0.36
PTGS1 P23219 3/20 0.36
ABCB11 O95342 1/20 0.33
PPARG P37231 1/20 0.33
NR1I3 Q14994 1/20 0.33
HTR6 P50406 7/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
KLK7 P49862 1/20 0.33
CD38 P28907 1/20 0.33
ACLY P53396 1/20 0.32
P2RX7 Q99572 1/20 0.32
MET P08581 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16618775 0.99 PTGES2 (0.36) PTGES2PTGS2PTGS1ABCB11PPARG
SCHEMBL16626613 0.93 KLK7 (0.39) PTGS2PTGS1ABCB11PPARGNR1I3
Hydrochloric Acid SCHEMBL16618964 0.92 KLK7 (0.38) PTGS2PTGS1ABCB11PPARGNR1I3
SCHEMBL16626549 0.92 TSHR (0.36) PTGS2PTGS1HTR6PDE4APDE4B
Hydrochloric Acid SCHEMBL16619382 0.92 TSHR (0.35) PTGS2PTGS1HTR6PDE4APDE4B
SCHEMBL16626494 0.89 HTR6 (0.42) HTR6KLK7P2RX7
SCHEMBL16626542 0.88 HTR6 (0.40) HTR6KLK7P2RX7
Hydrochloric Acid SCHEMBL16618921 0.88 HTR6 (0.41) HTR6KLK7P2RX7
SCHEMBL16626747 0.87 HTR6 (0.41) PTGS2PTGS1HTR6PDE4APDE4B
SCHEMBL16626763 0.87 HTR6 (0.42) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI PTGES2 362/4885PTGS2 390/4885PTGS1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.